CLINDETS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CLINDETS (CLINDETS).

How it works

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It also acts as a competitive inhibitor of bacterial ribosomal RNA methyltransferases.

What the body does with it

Metabolism	Hepatic metabolism primarily via CYP3A4 to active and inactive metabolites; some metabolites (N-demethyl, sulfoxide) have antibacterial activity.
Excretion	Approximately 10% of the dose is excreted unchanged in urine; the remainder is hepatically metabolized and eliminated via bile (fecal: ~40%) and urine as inactive metabolites.
Half-life	Terminal elimination half-life is 2.4-3 hours in adults; prolonged to 4-6 hours in severe hepatic impairment.
Protein binding	Clindamycin is 90-94% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent volume of distribution is approximately 0.6-0.8 L/kg, indicating extensive tissue penetration including skin and bone.
Bioavailability	Topical gel: approximately 5-10% systemically absorbed; vaginal cream: ~4% absorbed; oral: ~90% (not relevant for this formulation).
Onset of Action	Topical: Clinical improvement may be noted within 2-6 weeks of regular application; vaginal cream: symptom relief begins within 1-3 days.
Duration of Action	The pharmacodynamic effect persists for 8-12 hours after topical application, supporting twice-daily dosing; systemic dosing not applicable.

Classification & Brands

Dosing & administration

Clindamycin: 150-450 mg orally every 6 hours; 600-900 mg IV every 8 hours. Max: 1.8 g/day for severe infections.

Dosage form	SWAB
Renal impairment	No dose adjustment required for GFR >30 mL/min. For GFR 10-29 mL/min: no adjustment; for GFR <10 mL/min: no adjustment, but consider prolonging interval to every 12 hours if toxicity.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or use normal dose but monitor. Child-Pugh C: use with caution, reduce dose by 75% or avoid if severe impairment.
Pediatric use	Neonates: 5-10 mg/kg IV every 12 hours; Infants/Children: 10-40 mg/kg/day orally in 3-4 divided doses; IV: 20-40 mg/kg/day in 3-4 divided doses. Max: 1.8 g/day.
Geriatric use	Use with caution due to higher risk of C. difficile colitis. Dose reduction not required unless renal/hepatic impairment. Monitor renal function and adjust accordingly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CLINDETS (CLINDETS).

Breastfeeding	Excreted in human milk in low amounts (M/P ratio ~0.15). Manufacturer advises caution due to potential for adverse effects in nursing infant. Consider benefit-risk; may be used with monitoring if necessary.
Teratogenic Risk	FDA pregnancy category D. First trimester: Avoid due to potential teratogenic effects (cleft palate, cardiac defects) based on animal studies and limited human data. Second and third trimesters: Use only if clearly needed; may cause fetal harm including premature closure of ductus arteriosus and oligohydramnios.

Warnings & precautions

■ FDA Black Box Warning

Clindamycin can cause severe and potentially fatal colitis, including pseudomembranous colitis (Clostridioides difficile-associated diarrhea).

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to clindamycin, lincomycin, or any component of the formulation; history of antibiotic-associated colitis; previous allergic reactions to lincosamides.

Clinical Precautions

Precautions

May cause severe colitis (including pseudomembranous colitis). Overgrowth of non-susceptible organisms (e.g., fungi). Prolonged use may result in superinfection. Use with caution in patients with gastrointestinal disease, hepatic impairment, or atopic history.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

CLINDETS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CLINDETS (CLINDETS).

How it works

What the body does with it

Metabolism	Hepatic metabolism primarily via CYP3A4 to active and inactive metabolites; some metabolites (N-demethyl, sulfoxide) have antibacterial activity.
Excretion	Approximately 10% of the dose is excreted unchanged in urine; the remainder is hepatically metabolized and eliminated via bile (fecal: ~40%) and urine as inactive metabolites.
Half-life	Terminal elimination half-life is 2.4-3 hours in adults; prolonged to 4-6 hours in severe hepatic impairment.
Protein binding	Clindamycin is 90-94% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent volume of distribution is approximately 0.6-0.8 L/kg, indicating extensive tissue penetration including skin and bone.
Bioavailability	Topical gel: approximately 5-10% systemically absorbed; vaginal cream: ~4% absorbed; oral: ~90% (not relevant for this formulation).
Onset of Action	Topical: Clinical improvement may be noted within 2-6 weeks of regular application; vaginal cream: symptom relief begins within 1-3 days.
Duration of Action	The pharmacodynamic effect persists for 8-12 hours after topical application, supporting twice-daily dosing; systemic dosing not applicable.

Classification & Brands

Dosing & administration

Clindamycin: 150-450 mg orally every 6 hours; 600-900 mg IV every 8 hours. Max: 1.8 g/day for severe infections.

Dosage form	SWAB
Renal impairment	No dose adjustment required for GFR >30 mL/min. For GFR 10-29 mL/min: no adjustment; for GFR <10 mL/min: no adjustment, but consider prolonging interval to every 12 hours if toxicity.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or use normal dose but monitor. Child-Pugh C: use with caution, reduce dose by 75% or avoid if severe impairment.
Pediatric use	Neonates: 5-10 mg/kg IV every 12 hours; Infants/Children: 10-40 mg/kg/day orally in 3-4 divided doses; IV: 20-40 mg/kg/day in 3-4 divided doses. Max: 1.8 g/day.
Geriatric use	Use with caution due to higher risk of C. difficile colitis. Dose reduction not required unless renal/hepatic impairment. Monitor renal function and adjust accordingly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CLINDETS (CLINDETS).

Breastfeeding	Excreted in human milk in low amounts (M/P ratio ~0.15). Manufacturer advises caution due to potential for adverse effects in nursing infant. Consider benefit-risk; may be used with monitoring if necessary.
Teratogenic Risk	FDA pregnancy category D. First trimester: Avoid due to potential teratogenic effects (cleft palate, cardiac defects) based on animal studies and limited human data. Second and third trimesters: Use only if clearly needed; may cause fetal harm including premature closure of ductus arteriosus and oligohydramnios.

Warnings & precautions

■ FDA Black Box Warning

Clindamycin can cause severe and potentially fatal colitis, including pseudomembranous colitis (Clostridioides difficile-associated diarrhea).

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to clindamycin, lincomycin, or any component of the formulation; history of antibiotic-associated colitis; previous allergic reactions to lincosamides.